Participants 272 523 10
for childhood acute lymphoblastic leukaemia (UKALL X) randomised patients aged 0-14 years inclusive with an initial white blood count of less than 100 x 10(9)/l to receive an early intensification block, a late intensification block, both, or neither.
Participants 524 656 5
The next trial, UKALL XI, for children aged 1-14 years, randomised between different central nervous system (CNS) directed therapies
Participants 689 789 4
all patients were also randomised between late intensification alone and both early plus late blocks
